SCHEMBL25280458

SCHEMBL25280458

CC(Oc1cc(B2OC(C)(C)C(C)(C)O2)ccc1[N+](=O)[O-])c1ccc(F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 1/20 0.42
▸ LIPG Q9Y5X9 1/20 0.42
▸ HSPB1 P04792 3/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ TDP1 Q9NUW8 2/20 0.33
▸ ATM Q13315 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ AAK1 Q2M2I8 2/20 0.32
▸ IDO1 P14902 1/20 0.32
▸ TDO2 P48775 1/20 0.32
▸ SLC6A4 P31645 1/20 0.32
▸ ALDH1A1 P00352 4/20 0.32
▸ HTT P42858 1/20 0.32
▸ ESR2 Q92731 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA9 Q16790 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ CSF1R P07333 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30566094 1.00 LPL (0.42) LPLLIPGHSPB1SMN1; SMN2TDP1
SCHEMBL25250508 1.00 LPL (0.42) LPLLIPGHSPB1SMN1; SMN2TDP1
SCHEMBL18582905 0.89 LPL (0.39) LPLLIPGTDP1AAK1SLC6A4
SCHEMBL18582906 0.89 LPL (0.39) LPLLIPGTDP1AAK1SLC6A4
SCHEMBL15283473 0.84 PDK1 (0.40) LPLLIPGSMN1; SMN2TDP1RAB9A
SCHEMBL17411095 0.83 LPL (0.36) LPLLIPGHSPB1SMN1; SMN2TDP1
SCHEMBL25891327 0.82 LPL (0.48) LPLLIPGAAK1IDO1TDO2
SCHEMBL24133606 0.82 LPL (0.48) LPLLIPGAAK1IDO1TDO2
SCHEMBL25238314 0.79 CYP19A1 (0.44) LPLLIPGHSPB1SMN1; SMN2TDP1
SCHEMBL30566075 0.79 CYP19A1 (0.44) LPLLIPGHSPB1SMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-04-10 — — US disclosed
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-02-20 — — US disclosed
WO-2023115142-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 — — WO disclosed
WO-2023115150-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 LPL 1442/4885LIPG 1293/4885HSPB1 3604/4885
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 LPL 1381/4885LIPG 1144/4885HSPB1 2548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback